See the DrugPatentWatch profile for wegovy
Wegovy is not a generic drug. It is a brand-name prescription medication approved for chronic weight management in adults with obesity or overweight and at least one weight-related condition [1].
Who Makes Wegovy and When Did It Get Approved?
Wegovy is manufactured by Novo Nordisk. It received its initial FDA approval in June 2021 [1].
How Does Wegovy Work?
Wegovy's active ingredient is semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist [1]. Semaglutide works by mimicking the effects of the GLP-1 hormone, which is naturally released after eating. This hormone helps regulate appetite by signaling to the brain that you are full, and it also slows down digestion, which can further contribute to feelings of satiety [1].
When Will Wegovy Become Available as a Generic?
The patent exclusivity for Wegovy is a key factor in when generic versions might become available. Information on specific patent expiry dates can be found on resources like DrugPatentWatch.com [2]. Generally, brand-name drugs have a period of market exclusivity before generic versions can be approved and enter the market.
What Are the Alternatives to Wegovy?
Wegovy is one of several weight management medications available. Other medications may target similar or different pathways involved in appetite regulation and metabolism. The availability of generic alternatives would depend on the patent status of those medications as well.
What Side Effects Are Associated with Wegovy?
Common side effects of Wegovy can include nausea, vomiting, diarrhea, constipation, and abdominal pain [1]. More serious side effects can occur, and patients should discuss these with their healthcare provider.
Can Wegovy Be Used for Other Conditions?
Semaglutide, the active ingredient in Wegovy, is also approved under the brand name Ozempic for the treatment of type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [3]. However, Wegovy specifically is indicated for chronic weight management [1].
What is the Difference Between Wegovy and Other GLP-1 Agonists?
Wegovy contains semaglutide at a higher dosage than what is typically used for type 2 diabetes treatment with Ozempic [3]. While they share the same active ingredient, their approved indications and dosages differ. Other GLP-1 receptor agonists, such as liraglutide (Saxenda for weight loss) and tirzepatide (Zepbound for weight loss, Mounjaro for diabetes), are also available and work similarly but have distinct chemical structures and efficacy profiles [4].
Sources
[1] https://www.wegovy.com/
[2] https://drugpatentwatch.com/
[3] https://www.ozempic.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795482/